ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ϲѶ | J9¼¯ÍÅÔìÒ©¼¯ÍŸ»ÂíËá±û·ÓÌæŵ¸£Î¤»¯Ñ§Ô­ÁÏÒ©×¢²áÉêÇë»ñÅú£¡

ÈÕÆÚ£º

2024Äê03ÔÂ02ÈÕ 14:03

½üÈÕ £¬J9¼¯ÍÅÊÕµ½¹ú¶ÈÒ©Æ·¼à¶½ÖÎÀí¾ÖºË׼ǩ·¢µÄ¹ØÓÚÔ­ÁÏÒ©¸»ÂíËá±û·ÓÌæŵ¸£Î¤µÄ¡¶»¯Ñ§Ô­ÁÏÒ©ÉÏÊÐÉêÇëºË׼֪ͨÊé¡· ¡£

 

935bf79b-0d75-41d1-ab54-a56d2c2e1de8

 

¹ØÓÚ¸»ÂíËá±û·ÓÌæŵ¸£Î¤

¸»ÂíËá±û·ÓÌæŵ¸£Î¤£¨TAF£© £¬ÊÇÒ»ÖÖÒ½ÖγÉÈ˺ÍÇàÉÙÄ꣨12ËêÒÔÉÏ £¬Ìå³ÁÖÁÉÙΪ35kg£©ÂýÐÔÒÒÐ͸ÎÑ×£¨HBV£©µÄÇ¿¿¹²¡¶¾Ò©Îï ¡£Æ¾¾ÝÃÀ¹úAASLD¡¶ÂýÐÔÒÒÐ͸ÎÑ×Ô¤·À¡¢Õï¶ÏºÍÒ½ÖΣ¨2018Ä꣩¡·¡¢ÖлªÒ½Ñ§»á¡¶ÂýÐÔÒÒÐ͸ÎÑ×»ù²ãÕïÁÆÖ¸ÄÏ£¨2020Ä꣩¡·¡¢¡¶ÂýÐÔÒÒÐ͸ÎÑ×·ÀÖÎÖ¸ÄÏ£¨2019Äê°æ£©¡·µÈ¹úÄÚ±íȨÍþÖ¸ÄϾùÍƼö¸»ÂíËá±û·ÓÌæŵ¸£Î¤Ôì¼Á×÷ΪҽÖÎÂýÐÔÒÒÐ͸ÎÑ×µÄÁÙ´²Ò»Ïß¿¹²¡¶¾Ò½ÖÎÓÃÒ©Ö®Ò» ¡£

¸»ÂíËá±û·ÓÌæŵ¸£Î¤ÊǸ»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥µÄÉý¼¶°æ £¬¿Ë·þÁ˲¿ÃŸ»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥µÄ±×¶Ë £¬Æ䰲ȫÐÔºÍÓÐЧÐÔ¾ù¸ßÓÚºóÕß ¡£¸»ÂíËá±û·ÓÌæŵ¸£Î¤½Ï¸»ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥Ï¸°ûÄÚÒ©ÎïŨ¶È¸ß5.3±¶ £¬Ñª½¬ÄÚÒ©ÎïŨ¶ÈµÍ91% ¡£ÓëÔÚѪ½¬Öм±¾çË®½âΪÌæŵ¸£Î¤µÄÌæŵ¸£Î¤õ¥£¨TDF£©Ïà±È £¬TAFÔÚѪ½¬Öвû·¢³ö¸ü¸ßµÄ²»±äÐÔ £¬²¢ÔÚ°Ðϸ°ûÖдﵽ¸ü¸ßµÄϸ°ûÄÚˮƽ ¡£¾Ý±¨Â· £¬TAFÔÚ±ÈTDFµÍÊ®±¶µÄ¼ÁÁ¿Ï²úÉú¸ü¸ßµÄ¿¹²¡¶¾³ÉЧ £¬¶ÔÉöÖ°Äܺ͹ÇÃܶȵÄÓ°Ïì½ÏÓ× ¡£

 

 

¹ØÓÚJ9¼¯ÍÅÔìÒ©¼¯ÍÅ

J9¼¯ÍÅÔìÒ©¼¯ÍÅʼ´´ÓÚ1970Äê £¬×ܲ¿Î»ÓÚÕã½­ÎÂÁë £¬ÊÇÒ»¼Òרҵ´ÓÊÂÏÖ´úÖÐÒ©¡¢»¯Ñ§Ô­ÁÏÒ©¼°Ôì¼ÁÑз¢¡¢³ö²úºÍÏúÊ۵ĸßм¼ÊõÆóÒµ ¡£¶àÄêÀ´ £¬¹«Ë¾Ê¼ÖÕ¶ÔÖÅ×ß²úѧÑÐÒ»Ì廯·· £¬ÉèÓгÉÊìµÄ¼¼Êõת»¯Æ½Ì¨ £¬³Áµã²¼¾ÖÐÄÄÔѪ¹Ü¡¢Éñ¾­ÏµÍ³µÈ¼²²¡ÁìÓò £¬Ä¿Ç°ÒÑÐγɓÒÔÌìȻֲÎïҩΪÌØÉ« £¬ÒÔÐÄÄÔѪ¹ÜºÍÉñ¾­ÏµÍ³ÓÃҩΪÖ÷ £¬ºôÎüϵͳ¼°ÆäËûÁìÓòÓÃҩΪ¸¨”µÄ²úÆ·ÖʾÖ £¬²¢Õ¼ÓÐÁ½´óȫ֪ʶ²úȨ²úÆ·——ÒøÐÓÒ¶µÎÍ衢ʯɼ¼î¼××¢ÉäÒº ¡£

 

Ê×Ò³ | J9¼¯ÍÅÓÐÏÞ¹«Ë¾¹ÙÍø

 

 

¡¾²Î¿¼Îļþ¡¿

[1] Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.0000000000000618. PMID: 25867913. 

[2] Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res. 2016 Jan;125:63-70. doi: 10.1016/j.antiviral.2015.11.009. Epub 2015 Nov 27. PMID: 26640223. 

[3] Li X, Tan XY, Cui XJ, Yang M, Chen C, Chen XY. Pharmacokinetics of Tenofovir Alafenamide Fumarate and Tenofovir in the Chinese People: Effects of Non-Genetic Factors and Genetic Variations. Pharmgenomics Pers Med. 2021 Oct 14;14:1315-1329. doi: 10.2147/PGPM.S329690. PMID: 34703277; PMCID: PMC8525415.

[4] ÎâÓ×ÑÞ,ÓÚºÆ,ÖÜÑó,µÈ. ¸»ÂíËá±û·ÓÌæŵ¸£Î¤Ó븻ÂíËáÌæŵ¸£Î¤¶þßÁß»õ¥¶ÔѪ֬ӰÏìµÄmeta·ÖÎö[J]. Ò©Îï²»Á¼·´Ó³ÔÓÖ¾,2021,23(11):584-591. DOI:10.3760/cma.j.cn114015-20211013-01064.

ÓйØÍƼö